# Study to Test the Safety of Increasing Multiple Doses of BAY2328065 Given by Mouth, How the Drug is Tolerated and Acts in the Human Body of Healthy Male Participants. Alteration of the Study Drug Effects by Another Drug and the Availability of the Drug Given in Different Formulations is Also Tested.

> **NCT04027192** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 50 (actual)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** BAY2328065 LSF
- **DRUG:** BAY2328065 tablet
- **DRUG:** Placebo LSF
- **DRUG:** Placebo tablet
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT04027192
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-31
- **Primary completion:** 2020-09-11
- **Final completion:** 2020-11-16
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04027192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04027192, "Study to Test the Safety of Increasing Multiple Doses of BAY2328065 Given by Mouth, How the Drug is Tolerated and Acts in the Human Body of Healthy Male Participants. Alteration of the Study Drug Effects by Another Drug and the Availability of the Drug Given in Different Formulations is Also Tested.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04027192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*